Dosimetric comparison of graphical optimization and inverse planning simulated annealing for brachytherapy of cervical cancer

Bin Tang, MSc1,2*, Xiangyu Liu, MSc3*, Xianliang Wang, MSc1,2, Shengwei Kang, MSc1,2, Pei Wang, MSc1, Jie Li, MSc1, Lucia Clara Orlandini, PhD3

1Radiation Oncology Department, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, 610041 Chengdu, China, 2Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, 610064 Chengdu, China, 3Key Laboratory for Bioengineering Science and Technology of Ministry of Education, Chongqing University, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, 400044 Chongqing, China

*Bin Tang and Xiangyu Liu contributed equally to this work.

Abstract

Purpose: Graphical optimization (GO) and inverse planning simulated annealing (IPSA) are the main treatment planning optimization techniques used in patients undergoing 3D brachytherapy treatment. This study aims to compare the dosimetric difference of plans optimized by GO and IPSA in cervical cancer brachytherapy.

Material and methods: 21 cervical cancer patients data sets consisted of computed tomography (CT) and magnetic resonance imaging (MRI), acquired with the Fletcher applicator in situ were transferred to the Oncentra brachytherapy planning system. For each patient, the treatment plan was initially optimized with GO to reach a maximal D90 tumor dose (6 Gy/fraction, 5 fractions), while keeping the dose to organs at risk (OARs) as low as possible. A second plan was then optimized with IPSA on the same CT images and data set (i.e., contours, catheters, and location of dwell points). Targets and OARs dose volume histograms and irradiation time were compared; data were analyzed with paired t-test; p value < 0.05 was considered statistically significant.

Results: The plans with both optimizations meet the clinical requirements. The mean D90 of the clinical target volume was comparable for GO and IPSA. Similar values (p > 0.05) of target V100, V150, V200, HI, and CI were registered for GO and IPSA optimizations. Bladder and rectum D1cc and D2cc obtained by GO resulted in larger values than those obtained by IPSA (p = 0.002). V75 for bladder and rectum were slightly higher for IPSA, but without statistical difference (p > 0.05). The irradiation time was comparable (p > 0.05).

Conclusions: In 3D brachytherapy of cervical cancer, GO and IPSA optimizations do not present a significant difference in target dose coverage; nevertheless, IPSA may reduce the maximum dose to normal tissue when compared with GO.

Key words: cervical cancer, 3D brachytherapy, optimization methods.
available treatment planning optimization techniques used in patients undergoing HDR 3D brachytherapy treatment.

In GO, the isodose lines on the transverse, sagittal, and coronal computed tomography (CT) images are adjusted manually. Then, the dwell positions and weights of the radioactive sources along the catheters are calculated to achieve the new dose distribution. GO is quite a fast method, and it is able to improve the coverage of the target while decreasing hot spots. Moreover, the optimization is not based on the anatomy.

The inverse planning approach [6] can be defined as a method of brachytherapy treatment planning, where the clinical objectives and treatment parameters are set up and adjusted along the optimization process to achieve the desired dose distribution. CT or magnetic resonance imaging (MRI) images are used not only to define the anatomy for visual assessment and dose calculation, but also to optimize the dose distribution [7]. Therefore, they provide to a physician additional flexibility and control to shape the dose distribution. In inverse planning, the anatomical features along with the dose constraints, constitute the starting point of the dose optimization process. In IPSA optimization, we have to define dose objectives for the target and dose constraints for OARs not only at the surface, but also inside the regions. A cost function with an increasing penalty for those failing to satisfy the predefined objectives and constraints is used. Then, the cost function is continuously decreased through an iterative process with an automatic adjustment of the sources and dwell weights [8], until an optimal solution is found. The main benefit of the inverse planning approach is that all clinical requirements (e.g., dose coverage and normal tissue protection) are simultaneously and automatically taken into account in the planning process.

In brachytherapy, the application of IPSA started in prostate cancer [9,10,11] and then extended to gynecological cancer [12,13,14]. However, several studies [15,16,17] have shown that IPSA gives promising results in target coverage, OARs sparing, and planning time in cervical cancer brachytherapy, either different applicators or the absence of interstitial implants might lead to different dosimetric results. This is the case in our study, which aims to compare the Fletcher applicator-based cervical brachytherapy plans optimized with GO and IPSA in terms of target and OARs dose-volume histogram (DVH) and irradiation times, when no interstitial implants are used.

### Material and methods

Twenty-one cervical cancer patients treated in our center were included in this retrospective study. Patient median age was 51 (range, 42-71), and they all presented with cervical squamous cell carcinoma with FIGO stages IIB (10 patients) and IIIB (11 patients). The patients were treated with EBRT with a prescription dose of 45 Gy in 25 fractions, and were subsequently scheduled with 5/6 fractions (6 Gy/fraction) for ICBT, based on MRI scans and gynecological examination; no interstitial needles were used due to patients’ positive responses after EBRT. For ICBT, the patients were arranged in a supine position on a vacuum bag with a thermoplastic mask modeled on their bodies. CT images with a slice thickness of 3 mm were acquired with the Philips Brilliance Big Bore (Philips, Eindhoven, The Netherlands), from L5 to 2 cm below the vulva with a CT/MRI Fletcher applicator (Elekta AB, Stockholm, Sweden) in situ. In the same configuration, T2-weighted MRI images of 3 mm thickness were acquired on a 1.5T Archivia MRI scanner (Philips Medical Systems B.V., Eindhoven, The Netherlands) at the same day. CT and MRI data sets were imported into the Oncentra Brachy treatment planning system, version 4.3 (Elekta AB, Stockholm, Sweden) and manually registered. Following the international study on MRI-guided brachytherapy in locally advanced cervical cancer (EMBRACE study), the radiation oncologist identified and delineated the clinical target volume (CTV) as well as the OARs (bladder and rectum) on the MRI T2 images; then, they were copied to CT, based on the registration between CT and MRI images. No margins were added to the CTV and OARs, since the setup uncertainties and internal motions were minimal. The CTV prescribed dose was 6 Gy, whereas for the rectum and bladder, we strove to reach a dose as low as achievable. Considering that the OARs were exposed to the full EBRT dose of 45 Gy, physical dose constraints per fraction of 5.4 Gy for the bladder and 4.2 Gy for the rectum were calculated with the EQD2 model. An experienced medical physicist dedicated to brachytherapy treatment plans (department workload 30 to 35 treatments per day) optimized the ICBT plan, and GO technique was used as first. During GO optimization, the global-local cursor was set to the middle, and 2.5 mm spacing of dwell points of a microSelectron HDR 192Ir v2r source was applied. A second plan was then obtained using IPSA optimization, using the same parameters (i.e., contours, catheters, or location of dwell points), while setting the dwell time deviation constraint to 0.4. In Table 1, the dwell time deviation constraint was set to 0.4.

| ROI          | Usage | Margin | Surface Weight | Min | Max | Weight | Volume |
|--------------|-------|--------|----------------|-----|-----|--------|--------|
| CTV          | Ref. target | –      | 100            | 6.0 | –   | –      | –      |
| Bladder      | Organ | –      | –              | –   | –   | 80     | –      |
| Rectum       | Organ | –      | –              | –   | 4.0 | 80     | –      |
| Sigmoid      | Organ | –      | –              | –   | 4.0 | 80     | –      |

*CTV – clinical target volume*
the objectives and constraints for the CTV and OARs used in the clinical practice of our center are shown. For the target dose coverage comparison, the volume receiving 100%, 150%, and 200% of prescription dose ($V_{100}$, $V_{150}$, and $V_{200}$, respectively), the conformity index (CI) and the homogeneity index (HI) were evaluated. CI and HI were defined as:

$$HI = \frac{V_{100} - V_{150}}{V_{100}}$$

(1)

$$CI = \frac{V_{CTV,ref}}{V_{CTV}}$$

(2)

where $V_{CTV,ref}$ is the target volume covered by the prescription dose, $V_{CTV}$ is the target volume, and $V_{ref}$ is the total volume covered by the prescription dose. For the OARs, the maximum doses received by 1 and 2 cm$^3$ ($D_{1cc}$ and $D_{2cc}$, respectively) and the volume receiving 75% of the prescription dose ($V_{75}$) for the bladder and rectum were extracted from the DVH and used for the comparison; $\alpha/\beta = 3$ was used in the determination of EQD$_2$ [18]. The paired $t$-test was performed using SPSS19.0 (SPSS Inc., Chicago, USA), and $p < 0.05$ was considered statistically significant.

### Results

The DVH dosimetric results obtained for the CTV and OARs for both optimizations are reported in Table 2. The datasets of the 21 patients are shown as the mean ± standard deviation ($x \pm s$); the mean volume of CTV is 35 cc (range, 23-60 cc).

For CTV $V_{100}$, $V_{150}$, and $V_{200}$ for both optimization techniques gave similar mean values without a statistical difference ($p > 0.05$); the same behavior ($p > 0.05$) was registered for HI and CI. The comparison of CTV $V_{100}$, $V_{150}$, and $V_{200}$ for each patient and optimization technique is shown in Figure 1.

When considering the OARs, no statistical difference was observed for the bladder and rectum $V_{75}$ for both optimizations, whereas IPSA plans registered the bladder and rectum $D_{1cc}$ and $D_{2cc}$ values significantly lower than those obtained with GO ($p = 0.002$), appearing to have a better ability to control high doses. Figure 2 shows the isodose distribution on sagittal view of both IPSA and GO plans.

After normalization to a source strength of 38.830 cGy.cm$^2$.h$^{-1}$, the mean irradiation time over 21 patients for GO and IPSA was 417.2 ±75.1 s and 407.9 ±62.4 s, respectively, with no statistical difference ($t = 0.632$, $p = 0.534$); the results obtained for each patient are reported in Figure 3A. However, the dwell point weight (DPW) distribution varied for GO and IPSA, as shown in Figure 3B, for a particular patient. IPSA demonstrated a greater

### Table 2. CTV and OARs DVH parameters of 21 patients, obtained with GO and IPSA optimizations techniques

| Parameter          | GO               | IPSA              | $t$   | $p$ value |
|--------------------|------------------|-------------------|-------|-----------|
| CTV $V_{100}$ (%)  | 87.46 ±3.97      | 86.81 ±4.52       | 0.640 | 0.529     |
| $V_{150}$ (%)      | 53.71 ±3.04      | 54.61 ±3.13       | 0.795 | 0.436     |
| $V_{200}$ (%)      | 32.27 ±6.64      | 33.61 ±3.51       | 1.093 | 0.287     |
| HI                 | 0.38 ±0.05       | 0.37 ±0.06        | 1.002 | 0.328     |
| CI                 | 0.53 ±0.10       | 0.57 ±0.11        | 1.384 | 0.182     |
| Bladder $D_{1cc}$ (Gy) | 3.35 ±1.45     | 3.12 ±1.40        | 3.596 | 0.002*    |
|                   | 3.02 ±1.36       | 2.81 ±1.31        | 3.490 | 0.002*    |
| $V_{75}$ (cc)      | 1.04 ±1.46       | 1.56 ±3.05        | 0.824 | 0.420     |
| Rectum $D_{1cc}$ (Gy) | 3.38 ±0.90      | 3.02 ±0.94        | 3.682 | 0.002*    |
|                   | 2.98 ±0.84       | 2.61 ±0.86        | 3.751 | 0.002*    |
| $V_{75}$ (cc)      | 0.51 ±0.52       | 0.52 ±0.72        | 0.092 | 0.928     |

*p ≤ 0.05

CTV – clinical target volume, OARs – organs at risk, DVH – dose-volume histogram, GO – graphical optimization, IPSA – inverse planning simulated annealing, HI – homogeneity index, CI – conformity index

**Fig. 1.** Clinical target volume (CTV) $V_{100}$, $V_{150}$, and $V_{200}$ obtained with graphical optimization (GO) and inverse planning simulated annealing (IPSA) optimization techniques
range of relative dwell weight than GO. In IPSA, only 17 out of 44 dwell positions were effectively used and some specific points had relatively large dwell times, whereas in GO, a smoother distribution of DPW was shown and none of the dwell points were completely turned off.

**Discussion**

To date, the Groupe Européen de Curiethérapie in the European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) and the American Brachytherapy Society (ABS) have not recommended an optimization method for ICBT of cervical cancer. Two previous dosimetric studies [19,20] conducted in our center showed that ICBT optimized by GO and IPSA, respectively, can both provide good target coverage and maintain low-dose to OARs when combined with EBRT. Through further comparison, this study shows that GO and IPSA plans do not have a significant difference in target volume dose distribution, homogeneity, and conformity for ICBT of cervical cancer. Although Hsu et al. [21] compared plans of prostate cancer optimized by GO or IPSA and they found that IPSA plan was superior to GO plan in target (V100), HI, and CI, and the dose of bladder and rectum was lower in IPSA plan. The main reason for this discrepancy between Hsu’s study and ours is due to limited number of Fletcher applicator catheters used, resulting in a small optimization space of dwell position and weight. Therefore, the potential and flexibility of IPSA in our study was not as obvious as in multichannel implanting brachytherapy. Another limitation of this study is that only surface dose points were set as the objectives in IPSA optimization process, particularly Dmin for the CTV and Dmax for the OARs, and no DVH parameters were used. However, these results revealed that IPSA plans are still better at controlling the maximum dose points of the bladder and rectum.

GO and IPSA both depend on the experience and skill of planners. In GO optimization, the isodose line is manually dragged to improve dose coverage. Although GO is an intuitive and effective optimization tool, it ob-
Comparison of GrO and IPSA

Conclusions

For ICBT of cervical cancer, plans optimized with GO and IPSA may result in no significant difference in target dose; however, IPSA may reduce the maximum dose to surrounding normal tissues. Nevertheless, in this study, no significant difference was found for V20, whereas DPW distribution indeed varies with optimization method for a particular case, which agrees with the conclusion from Hsu et al. [21]. The inhomogeneity of DPW, as shown in Figure 3B, is a IPSA problem and those points with large dwell time might result in an overdose to normal tissue around targets where no explicit OARs have been contoured [16]. Setting a higher dwell time deviation constraint and drawing support structures around applicators might be helpful [15].

Acknowledgements

This research has been financed by the Key Research and Development Project of Sichuan, no. 2018GZ0197.

Disclosure

Authors report no conflict of interest.

References

1. Eifel PJ, Winter K, Morris M et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22: 872-880.
2. Lindegaard JC, Fokdal LU, Nielsen SK et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 2013; 52: 1510-1519.
3. Nomden CN, de Leeuw AA, Roessink JM et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 2013; 107: 69-74.
4. Gupta P, Aich RK, Deb AR. Acute complications following intracavitary high-dose-rate brachytherapy in uterine cancer. J Contemp Brachytherapy 2014; 6: 276-281.
5. Teke F, Yöneş A, Teke M et al. Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. Contemp Oncol (Polix) 2015; 19: 130-136.
6. Lessard E. Development and clinical introduction of an inverse planning dose optimization by simulated annealing (IPSA) for high dose rate brachytherapy. Med Phys 2004; 31: 2935-2935.
7. Tunipumiamorn L, Lohasammakul S, Dankulchai P et al. Comparison of impact of target delineation of computed tomography- and magnetic resonance imaging-guided brachytherapy on dose distribution in cervical cancer. J Contemp Brachytherapy 2018; 10: 418-424.
8. Jamema SV, Sharma S, Mahanshetty U et al. Comparison of IPSA with dose-point optimization and manual optimization for interstitial template brachytherapy for gynecologic cancers. Brachytherapy 2011; 10: 306-312.
9. Messing EM, Zhang J, Rubens DJ et al. Intraoperative optimized inverse planning for prostate brachytherapy: Early experience. Int J Radiat Oncol Biol Phys 1999; 44: 801-808.
10. Lessard E, Pouliot J. Inverse planning anatomy-based dose optimization for HDR-brachytherapy of the prostate using fast simulated annealing algorithm and dedicated objective function. Med Phys 2001; 28: 773-779.
11. Kolkman-Deurloo IK, Deyle YG, Jansen PP et al. Anatomy based inverse planning in HDR prostate brachytherapy. Radiother Oncol 2004; 73: 73-77.
12. Lessard E, Hsu IC, Pouliot J. Inverse planning dose optimization of interstitial gyn-template high-dose-rate brachytherapy boost. Int J Radiat Oncol Biol Phys 2001; 51: 329.
13. Lessard E, Hsu IC, Pouliot J. Inverse planning for interstitial gynecologic template brachytherapy: truly anatomy-based planning. Int J Radiat Oncol Biol Phys 2002; 54: 1243-1251.
14. Dewitt KD, Hsu IC, Speight J et al. 3D inverse treatment planning for the tandem and ovoid applicator in cervical cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1270-1274.
15. Trnková P, Pötter R, Baltas D et al. New inverse planning technology for image-guided cervical cancer brachytherapy: description and evaluation within a clinical frame. Radiother Oncol 2009; 93: 331-340.
16. Trnková P, Baltas D, Karabis A et al. A detailed dosimetric comparison between manual and inverse plans in HDR intracavitary/interstitial cervical cancer brachytherapy. J Contemp Brachytherapy 2010; 2: 163-170.
17. Krishnamurthy D, Cunha AJ, Hsu IC et al. 696 poster Using IPSA algorithm in dose planning for cervix HDR brachytherapy with the Utrecht applicators. first phase results. Radiother Oncol 2011; 99: S278.
18. Grigsby PW, Williamson JP, Clifford Chao KS et al. Cervical tumor control evaluated with ICRU 38 reference volumes and integrated reference air kerma. Radiother Oncol 2001; 58: 19-23.
19. Wang X, Li J, Wang P et al. Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer. J Contemp Brachytherapy 2016; 8: 122-127.
20. Yin G, Wang P, Lang J et al. Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. J Contemp Brachytherapy 2016; 8: 221-232.
21. Hsu IC, Lessard E, Weinberg V et al. Comparison of inverse planning simulated annealing and geometrical optimization for prostate high-dose-rate brachytherapy. Brachytherapy 2004; 3: 147-152.